US2021230230A1PendingUtilityA1

Soluble Forms of Hendra and Nipah Virus G Glycoprotein

74
Assignee: HENRY M JACKSON FOUND ADVANCEMENT MILITARY MEDICINE INCPriority: Jul 9, 2004Filed: Jan 29, 2021Published: Jul 29, 2021
Est. expiryJul 9, 2024(expired)· nominal 20-yr term from priority
Inventors:Christopher C. BroderKatharine N. Bossart
C07K 16/11A61K 39/00C12N 2760/18271A61P 31/00C12N 2760/18222G01N 33/6854C07K 2319/40A61K 2039/505C12N 2710/24141A61K 39/12A61K 39/155C12N 7/00C07K 14/005C12N 2760/18234A61K 2039/575G01N 33/56983A61K 2039/6075C07K 14/07C07K 14/115C07K 16/1027
74
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

This invention relates to soluble forms of G glycoprotein from Hendra and Nipah virus. In particular, this invention relates to compositions comprising soluble forms of G glycoprotein from Hendra and Nipah virus and also to diagnostic and therapeutic methods using the soluble forms of G glycoprotein from Hendra and Nipah virus. Further, the invention relates to therapeutic antibodies including neutralizing antibodies, and vaccines for the prevention and treatment of infection by Hendra and Nipah viruses.

Claims

exact text as granted — not AI-modified
1 - 40 . (canceled) 
     
     
         41 . A monoclonal antibody specifically reactive to a polypeptide comprising a soluble form of the ectodomain of Nipah virus G protein. 
     
     
         42 . A vaccine for preventing or treating infection of a patient by Nipah virus comprising the antibody of claim  1 . 
     
     
         43 . A method of detecting infection by a Hendra virus comprising detecting Nipah virus antigens or antibodies to Nipah virus in a sample obtained from a subject suspected of being infected using the monoclonal antibody of claim  1 .

Join the waitlist — get patent alerts

Track US2021230230A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.